Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related
to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and efforts to add Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ECN

16. Specific lobbying issues

General issues related to foreign direct investment in the United States, including all provisions of S3274 and HR5910 "Global Investment in American Jobs Act of 2012"

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Sanofi SA, the foreign parent corporation of sanofi-aventis U.S. Inc., as disclosed on its LD-1

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization